Evidence map›Paper›PMID 36750457›Full record

ArticleAnnals of dermatology2023

Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study.

Tae Young Han, Dong Hyun Shim, Yu Jin Lee, Young Bok Lee, Ha Yeh Rin Koo, Min Kyung Shin, Tae Eun Kim, Yong Hyun Jang, Jin Seon Bang, Hyung Don Kook and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Tae Young Han *Department of Dermatology, College of Medicine, Eulji University, Daejeon, Korea.ORCID https://orcid.org/0000-0003-0317-9635
Dong Hyun Shim *Department of Dermatology, College of Medicine, Chosun University, Gwangju, Korea.ORCID https://orcid.org/0000-0001-7060-0819
Yu Jin LeeDepartment of Dermatology, College of Medicine, Eulji University, Daejeon, Korea.ORCID https://orcid.org/0000-0003-0677-4560
Young Bok LeeDepartment of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-8642-2479
Ha Yeh Rin KooDepartment of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0001-9758-7685
Min Kyung ShinDepartment of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.ORCID https://orcid.org/0000-0001-9834-7931
Tae Eun KimDepartment of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea.ORCID https://orcid.org/0000-0001-6617-0510
Yong Hyun JangDepartment of Dermatology, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0003-1706-007X
Jin Seon BangDepartment of Dermatology, School of Medicine, Kyungpook National University, Daegu, Korea.ORCID https://orcid.org/0000-0001-8475-2143
Hyung Don KookDepartment of Dermatology, National Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0001-6687-2125
Jiyoung AhnDepartment of Dermatology, National Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-6766-9978
Hye Jung JungDepartment of Dermatology, National Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0003-0995-5711
Chan Ho NaDepartment of Dermatology, College of Medicine, Chosun University, Gwangju, Korea. chna@chosun.ac.kr.ORCID https://orcid.org/0000-0001-5259-5382
Chosun University · KRNational Medical Center · KRKyung Hee University · KRKyungpook National University · KRCatholic University of Korea · KREulji University · KR

Funding

Chosun University
6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) patients usually wonder if their condition will worsen after vaccination or if they should continue with the treatment they are receiving. Considering that many patients treated with dupilumab had previously experienced severe AD symptoms and flares, the concerns are more understandable.

objectiveThis study aimed to investigate the safety of the coronavirus disease 2019 (COVID-19) vaccination in patients with AD treated with dupilumab.

methodsWe enrolled 133 patients (101 dupilumab-treated and 32 systemic oral agents-treated as control group) with AD from six hospitals. Patients were asked about worsening pruritus and AD (5-point Likert scale) after vaccination. AD variables (eczema area and severity index [EASI], investigator's global assessment [IGA], itch numerical rating scale [NRS], sleep NRS, and patient-oriented eczema measure [POEM]) were compared pre- and post-vaccination. Adverse reactions to the COVID-19 vaccination were observed.

resultsThe incidence of adverse reactions to COVID-19 vaccines and worsening AD symptoms in dupilumab-treated patients were not significantly different compared with that in the control group. The itch NRS score increased significantly after vaccination (

conclusionNo serious adverse reactions were observed in patients with AD after COVID-19 vaccination. Exacerbation of pruritus and AD symptoms was observed but was mostly mild and transient.

Indexed as

Atopic dermatitisCOVID-19 vaccinesDupilumab

Identifiers

PMID36750457
PMCPMC9905853
OpenAlexW4318452931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.